HN user

sungam

396 karma

Academic Mohs Surgeon. I lead a research group focused on developing treatments to prevent skin cancer and finding better therapies for scarring and fibrosis. Co-founder @Fibrodyne.

Posts6
Comments139
View on HN

This is fantastic and I would do something similar if I had the same resources.

Whole genome sequencing and single cell sequencing are actually surprisingly inexpensive (compared to the cost of almost any cancer treatment) and there is a good argument that we should do this by default for any type of cancer for which there are not effective treatments.

I would encourage all patients to learn as much as possible about their own diagnosis. There may be clinical trials available in another centre that your clinician is not aware of or tumour-agnostic trials that target specific mutations that are present in a range of different cancers.

There is a good argument for allowing patients to try experimental treatments once standard treatments are exhausted. The provider liability issues could easily be solved by legislation. A bigger issue is that there will always be people who want to exploit vulnerable cancer patients by charging exorbitant amounts for plausible-sounding treatments which have no evidence base.

As an individual trying multiple experimental treatments at once is the logical approach if there is no other option. However it will not be possible to know which of these is effective and which have caused side effects so to develop more effective treatments we do need structured and carefully controlled clinical trials. Unfortunately there is a huge regulatory burden for any kind of clinical trial at present and this should be massively streamlined for cancer patients where even if the treatments cause harm the alternative is death.

Thanks for your kind words with regards to the app and well done for getting such a high score!. I agree that BCC is often subtle. My practice is also largely focused on skin cancer. I would say that the majority of melanomas (and SCCs) that I diagnose would be obvious to a patient that underwent a short period of focused training and checked their skin regularly. A possible explanation for the difference in our experience is that the incidence of skin cancer (and also atypical but benign moles) a lot higher in Australia than in the UK.

Lots of models out there but I would not trust any for diagnosis without review of a dermatologist yet. The challenge is unanticipated edge cases and managing risk/liability/regulation. I have no doubt that if a major AI company focused on this problem then these issues could be overcome with current technology but perhaps the market is not big enough to justify the investment required.

This is why dermatology involves risk management not just image interpretation. Yes the lesion will likely change with time. Realistically yes, if you have a melanoma that looks like a harmless mole then the diagnosis is likely to be delayed. But remember that these are a tiny proportion of all skin cancers and you are much more likely to get some other form of cancer - most of which occur internally and cannot be seen at all.

Unfortunately not that useful - we could do that now by taking a very small (e.g. 2mm) punch biopsy, and if it shows melanoma obviously that is helpful and the rest of the lesion needs to be removed. The issue is that a negative result doesn't exclude melanoma elsewhere in the lesion.

I have been working with a startup to try and develop a non-invasive molecular test for melanoma so hopefully this will be possible in the future.